## **AMENDMENTS TO THE SPECIFICATION**

- 1) Please replace the Sequence Listing, pages 1-3, currently found in the above referenced specification with the amended Sequence Listing, pages 1-3, herewith submitted.
- 2) Please replace the paragraph which begins on page 1, line 4 of the application, with the following paragraph:

## **Cross Reference to Related Applications**

This application is a divisional of US Serial No. 09/341,351, filed May 13, 1999, which is a continuation-in-part application of US Serial No. 09/080,080 filed May 15, 1998.

----

3) Please replace the paragraph found on page 13 of the specification, lines 13-18, with the paragraph shown below:

Deposit of a CHO cell line used to produce the recombinant protein described herein was made at the ATCC, 12301 Parklawn Drive, Rockville, MD, 20852, USA, on May 5, 1999, Deposit No. <u>PTA-8</u>. Since the strain referred to is being maintained under the terms of the Budapest Treaty, it will be made available to a patent office signatory to the Budapest Treaty.

---

4) Please replace the paragraph found on page 44 of the specification, lines 4-8, with the paragraph shown below:

Stable production cell lines that secrete high quantities of the IL2N88R mutein were developed by transfecting CHO(dhfr-) cells with the expression vector shown in Figure 20 (ATCC Deposit No. <u>PTA-8</u>). The individual elements of the IL2N88R expression vector are shown in the plasmid map (Fig.20). It shows CMVe/p = Cytomegalovirus early promoter; PA = SV40 polyadenylation signal sequence; and DHFR - dihydrofolate reductase expression cassette.